inXso is an innovation agency specializing in breakthrough, disruptive, and emerging technologies for healthcare, covering deep tech and nanotechnology solutions for medical, biomedical, and health technology. Following our motto, "We bridge the gap between medical research, the development of medical innovation, and international commercialisation," we provide essential support from ideation to robust international market models.
Our operations are based on an extensive network of experts in Europe and the Asia-Pacific region up to North America. We enhance patient safety by co-creating Safe-by-Design models, guiding clients through diverse international regulatory pathways, and accelerating market entry.
Our enhanced service portfolio integrates Strategic R&D Due Diligence (QARA, QMS/GCP compliance, and technical filing readiness) with high-value Global Market Access (HTA execution, reimbursement strategy, and PMS planning). We also operate the MTI25 Helsinki Summit Acceleration Platform, strategically unlocking specialized private capital for Emerging Medical Technologies, with a dedicated focus on FemTech funding. Our projects prioritize personalized and precision medicine, complex borderline cases, and high-risk solutions (implants, cell and gene therapeutics).